| Symbol | DVA |
|---|---|
| Name | DAVITA INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Misc Health and Biotechnology Services |
| Address | 2000 16TH STREET, DENVER, Colorado, 80202, United States |
| Telephone | +1 720 - 631-2100 |
| Fax | — |
| — | |
| Website | https://www.davita.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000927066 |
| Description | DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. Additional info from NASDAQ: |
📋 Joel Ackerman (Officer) plans to sell 51K shares of DaVita Inc. (at $191.50 each, total $9.9M) Filed: May 07, 2026 | ID: 000514
Read moreDaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
Read moreDaVita Inc. to Participate in the BofA Securities 2026 Health Care Conference
Read more📋 HEARTY JAMES O (Officer) plans to sell 2K shares of DAVITA INC. (at $169.28 each, total $370K) Filed: May 06, 2026 | ID: 000506
Read moreBERKSHIRE HATHAWAY INC 🔴 sold 1.2M shares of DAVITA INC. (DVA) at $149.84 ($182.9M) Transaction Date: May 01, 2026 | Filing ID: 207021
Read moreNew Form ARS - DAVITA INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001206774-26-000235 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - DAVITA INC. <b>Filed:</b> 2026-04-22 <b>AccNo:</b> 0001206774-26-000234 <b>Size:</b> 276 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT04428008 | Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients | Phase2 | COVID-19 | Completed | 2021-01-12 | 2023-01-19 | ClinicalTrials.gov |
| NCT04495907 | COVID-19 Progression in End-Stage Kidney Disease | — | SARS-CoV-2 Infection (Asymptomatic) | Completed | 2020-08-06 | 2021-08-31 | ClinicalTrials.gov |
| NCT04095039 | HiLo: Pragmatic Trial of Higher vs Lower Serum Phosphate Targets in Patients Un… | Na | All-cause Mortality | Terminated | 2020-03-11 | 2023-11-17 | ClinicalTrials.gov |
| NCT05032417 | Evaluating the Implementation of Evidence-Based Kidney Nutrition Practice Guide… | Na | Chronic Kidney Diseases | Unknown | 2019-09-17 | 2023-08-31 | ClinicalTrials.gov |
| NCT03791814 | A Prospective Cohort Study to Improve HCV Care in Dialysis Patients | Phase4 | Hepatitis C | Withdrawn | 2019-01-01 | 2019-06-30 | ClinicalTrials.gov |
| NCT03234010 | CSD170303: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes | Na | Smoking | Completed | 2017-07-18 | 2017-09-30 | ClinicalTrials.gov |
| NCT03233997 | CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes | Na | Smoking | Completed | 2017-07-18 | 2017-09-30 | ClinicalTrials.gov |
| NCT02358967 | Palm Tocotrienols in Chronic Hemodialysis (USA) | Na | End Stage Renal Disease | Completed | 2017-06-15 | 2020-08-31 | ClinicalTrials.gov |
| NCT03105804 | CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake i… | Na | Smoking | Completed | 2017-03-29 | 2017-10-27 | ClinicalTrials.gov |
| NCT03063034 | CSD1602: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From … | Na | Smoking | Completed | 2017-02-06 | 2017-03-13 | ClinicalTrials.gov |
| NCT03063047 | CSD1603: A Crossover Study to Evaluate the Exposure to "Tar" and Nicotine From … | Na | Smoking | Completed | 2017-02-06 | 2017-03-13 | ClinicalTrials.gov |
| NCT02730676 | Comparison of Pharmacokinetic Parameters Between Adopters of Electronic Cigaret… | — | Smoking | Completed | 2016-04-01 | 2016-08-01 | ClinicalTrials.gov |
| NCT02651428 | Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis … | Phase3 | Kidney Failure, Chronic | Completed | 2015-12-01 | 2018-10-01 | ClinicalTrials.gov |
| NCT02593149 | Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap | Na | End Stage Renal Disease (ESRD) | Completed | 2015-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT02360748 | A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal D… | Na | End-Stage Renal Disease | Completed | 2015-10-01 | 2017-09-15 | ClinicalTrials.gov |
| NCT02500667 | A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects | Phase1 | Drug Interaction Potentiation | Completed | 2015-06-01 | 2015-08-01 | ClinicalTrials.gov |
| NCT02323438 | Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers … | Na | Smoking | Completed | 2014-12-01 | 2015-05-01 | ClinicalTrials.gov |
| NCT02044614 | Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis | Na | Functionally Anuric | Terminated | 2014-05-01 | 2016-04-01 | ClinicalTrials.gov |
| NCT01623583 | Effect of Including Synera® in Discussions on Dialysis Access Conversion in Pat… | Phase4 | Needle Phobia | Terminated | 2014-04-01 | 2015-03-01 | ClinicalTrials.gov |
| NCT02019225 | A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration | Na | End Stage Renal Disease | Terminated | 2013-12-18 | 2017-04-30 | ClinicalTrials.gov |
| NCT01873534 | A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodia… | Phase2 | Anemia of Chronic Disease | Terminated | 2013-06-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT02373215 | Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic… | Phase1 | Uremic Pruritus | Completed | 2013-04-01 | 2013-11-01 | ClinicalTrials.gov |
| NCT00895401 | DaVita Assessment of Nutritional Supplement Effects (DANSE) | Phase4 | Malnutrition | Completed | 2009-04-01 | — | ClinicalTrials.gov |
| NCT00785629 | A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphor… | Na | Chronic Kidney Disease | Completed | 2009-02-01 | 2011-07-01 | ClinicalTrials.gov |
| NCT00692419 | Pain, Sexual Dysfunction, and Depression in Hemodialysis Patients | Na | End Stage Renal Disease | Completed | 2008-11-01 | 2012-01-01 | ClinicalTrials.gov |
| NCT00561093 | Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients | Phase3 | Hypoalbuminemia | Completed | 2008-02-01 | 2011-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PD21872AA | Other | Approved | Smoking | COMPLETED | NCT03063047 |
| PD21871AA | Other | Approved | Smoking | COMPLETED | NCT03063047 |
| PD21864AB | Other | Approved | Smoking | COMPLETED | NCT03063034 |
| PD21864AA | Other | Approved | Smoking | COMPLETED | NCT03063034 |
| Dialysis session of at least 4.25 hours | Other | Approved | End Stage Renal Disease | TERMINATED | NCT02019225 |
| Hemodialysis | Other | Approved | All-cause Mortality | TERMINATED | NCT04095039 |
| FMX-8 | Other | Phase PHASE2 | Anemia of Chronic Disease | TERMINATED | NCT01873534 |
| Standard Needle Phobia Intervention | Other | Phase PHASE4 | Needle Phobia | TERMINATED | NCT01623583 |
| Enhanced Needle Phobia Intervention | Other | Phase PHASE4 | Needle Phobia | TERMINATED | NCT01623583 |
| Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis | Other | Approved | Functionally Anuric | TERMINATED | NCT02044614 |
| Rifampin | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT02500667 |
| N91115 | Other | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT02500667 |
| FT21097 | Other | Approved | Smoking | COMPLETED | NCT03234010 |
| FT21096 | Other | Approved | Smoking | COMPLETED | NCT03234010 |
| FT21093 | Other | Approved | Smoking | COMPLETED | NCT03234010 |
| FT21092 | Other | Approved | Smoking | COMPLETED | NCT03234010 |
| FT21035 | Other | Approved | Smoking | COMPLETED | NCT03233997 |
| FT21034 | Other | Approved | Smoking | COMPLETED | NCT03233997 |
| FT21033 | Other | Approved | Smoking | COMPLETED | NCT03233997 |
| FT21018 | Other | Approved | Smoking | COMPLETED | NCT03233997 |
| FT21042 | Other | Approved | Smoking | COMPLETED | NCT03105804 |
| FT21044 | Other | Approved | Smoking | COMPLETED | NCT03105804 |
| FT21041 | Other | Approved | Smoking | COMPLETED | NCT03105804 |
| FT21039 | Other | Approved | Smoking | COMPLETED | NCT03105804 |
| Plant based high protein food items | Other | Approved | End-Stage Renal Disease | COMPLETED | NCT02360748 |
| Electronic Cigarette #2 | Other | Preclinical | Smoking | COMPLETED | NCT02730676 |
| Electronic Cigarette #1 | Other | Preclinical | Smoking | COMPLETED | NCT02730676 |
| Leading U.S. Nicotine Gum | Other | Approved | Smoking | COMPLETED | NCT02323438 |
| Electronic Cigarette #2 | Other | Approved | Smoking | COMPLETED | NCT02323438 |
| Electronic Cigarette #1 | Other | Approved | Smoking | COMPLETED | NCT02323438 |
| Usual Brand Cigarette | Other | Approved | Smoking | COMPLETED | NCT02323438 |
| ClearGuard HD End Cap | Other | Approved | End Stage Renal Disease (ESRD) | COMPLETED | NCT02593149 |
| Zepatier | Other | Phase PHASE4 | Hepatitis C | WITHDRAWN | NCT03791814 |
| Placebo | Other | Approved | End Stage Renal Disease | COMPLETED | NCT02358967 |
| TRF (Tocotrienol-rich-fraction) | Other | Approved | End Stage Renal Disease | COMPLETED | NCT02358967 |
| implementation of evidence-based nutrition practice guidelines | Other | Approved | Chronic Kidney Diseases | UNKNOWN | NCT05032417 |
| Heparin | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT02651428 |
| Neutrolin | Other | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT02651428 |
| Nalbuphine HCL ER | Other | Phase PHASE1 | Uremic Pruritus | COMPLETED | NCT02373215 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| Thymalfasin | Other | Phase PHASE2 | COVID-19 | COMPLETED | NCT04428008 |
| implementation of evidence-based nutrition practice guidelines | OTHER | Approved | Chronic Kidney Diseases | UNKNOWN | NCT05032417 |
| Heparin | DRUG | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT02651428 |
| Neutrolin | DRUG | Phase PHASE3 | Kidney Failure, Chronic | COMPLETED | NCT02651428 |
| Rifampin | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT02500667 |
| N91115 | DRUG | Phase PHASE1 | Drug Interaction Potentiation | COMPLETED | NCT02500667 |
| Nalbuphine HCL ER | DRUG | Phase PHASE1 | Uremic Pruritus | COMPLETED | NCT02373215 |
| Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis | OTHER | Approved | Functionally Anuric | TERMINATED | NCT02044614 |
| Dialysis session of at least 4.25 hours | OTHER | Approved | End Stage Renal Disease | TERMINATED | NCT02019225 |
| FMX-8 | DRUG | Phase PHASE2 | Anemia of Chronic Disease | TERMINATED | NCT01873534 |
| Feedback intervention | BEHAVIORAL | Approved | End Stage Renal Disease | COMPLETED | NCT00692419 |
| Symptom management nurse intervention | BEHAVIORAL | Approved | End Stage Renal Disease | COMPLETED | NCT00692419 |
| Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus | OTHER | Approved | End-Stage Renal Disease | COMPLETED | NCT01116947 |
| Placebo | DRUG | Approved | Chronic Kidney Disease | COMPLETED | NCT00785629 |
| Sevelamer Carbonate | DRUG | Approved | Chronic Kidney Disease | COMPLETED | NCT00785629 |
| Lanthanum Carbonate | DRUG | Approved | Chronic Kidney Disease | COMPLETED | NCT00785629 |
| Calcium acetate | DRUG | Approved | Chronic Kidney Disease | COMPLETED | NCT00785629 |
| Placebo pill imitating pentoxiphylline | DRUG | Phase PHASE3 | Hypoalbuminemia | COMPLETED | NCT00561093 |
| pentoxiphylline | DRUG | Phase PHASE3 | Hypoalbuminemia | COMPLETED | NCT00561093 |